Symbiotec Pharmalab IPO: Steroid API Leader Eyes Capital-Market Debut

August 21, 2026 Bilkul Bazaar

Symbiotec Pharmalab’s ₹1,757-Crore IPO to Open August 24; Founder Anil Satwan Eyes Global Expansion

From a Backyard Lab to a ₹1,757-Crore IPO: Symbiotec’s Anil Satwan Bets on Steroid APIs for Global Growth

Bilkul Bazaar | By Rafat Quadri

Ahmedabad

Symbiotec Pharmalab Limited, the Indore-based biopharmaceutical company specialising in corticosteroid and steroid-hormone Active Pharmaceutical Ingredients (APIs), is set to enter the capital market with a ₹1,757-crore Initial Public Offer (IPO), with the issue opening for subscription on August 24 and closing on August 27, 2026.

The company’s management, led by CMD Anil Satwan, CFO Raghavender Ramachandran, General Manager, CMD Office Shubham Saboo, Head – Strategy, CMD Office Kapil Mishra, and Head – BD Injectable Krishna Satwan, interacted with the media in Ahmedabad on Thursday. They were accompanied by Joshika Mondal, AVP, Motilal Oswal Investment Advisors.

The IPO comprises a fresh issue of up to ₹150 crore and an offer for sale of up to ₹1,607 crore by existing shareholders. The price band has been fixed at ₹938-₹988 per equity share, with a minimum bid of 15 shares. The company proposes to use the net proceeds from the fresh issue primarily towards repayment or prepayment of certain outstanding borrowings and general corporate purposes. The shares are proposed to be listed on both BSE and NSE, with BSE as the designated stock exchange.

From a scientific curiosity to a global business

For Anil Satwan, Symbiotec represents a journey that began not with a conventional corporate blueprint but with an intense fascination for science and molecules.

A higher-studies student of science, Satwan developed a deep interest in molecular research and began experimenting in the backyard of his father’s clinic. That early curiosity eventually developed into a research-driven pharmaceutical enterprise that today serves more than 200 customers across over 40 countries.

Anil Satwan says, “What started as a deep curiosity about molecules and a small research effort has grown into an organisation with a global footprint. Our ambition now is to build on this foundation, expand our portfolio across steroidal hormones and establish Symbiotec as a leading global player by combining scientific capability with India’s cost and manufacturing advantages.”

Founded with R&D operations in 1995 and commercial manufacturing beginning in 2004, Symbiotec has built its business around corticosteroid and steroid-hormone APIs, operating as a Contract Development and Manufacturing Organization (CDMO).

38.20% global corticosteroid API market share

Symbiotec has emerged as a significant global player in corticosteroid APIs, with the company reporting a 38.20% global market share and FY2026 revenue of ₹869.15 crore.

Its portfolio spans corticosteroid APIs and steroidal-hormone APIs, with the company claiming a 23.80% market share in steroidal-hormone APIs and a presence across the top 10 APIs in the two categories.

One of its principal differentiators is vertical integration. Symbiotec describes itself as India’s only fully vertically integrated manufacturer of steroid-hormone APIs, giving it control across the manufacturing chain from raw-material synthesis to final API production.

The company operates two industrial-scale manufacturing plants with combined capacity of 584.67 metric tonnes of chemical synthesis and 300 kilolitres of fermentation.

Its manufacturing and development capabilities span three technology platforms — organic chemistry, biotechnology and complex injectables. The company has also developed capabilities in specialised injectable technologies, including Double Chamber Vials through backward integration.

“Complex injectables can be a major growth opportunity”

The company’s injectable business is another area that management sees as strategically important as Symbiotec expands beyond its established API franchise.

Krishna Satwan, Head – BD Injectable:
“Our focus in injectables is on building differentiated capabilities rather than competing only on volumes. Complex injectable technologies, backed by our chemistry and biotechnology platforms, can open new opportunities with global pharmaceutical customers and strengthen our position across the value chain.”

The company has also received regulatory approvals from major international authorities, including the US FDA, EU-GMP and Korea’s Ministry of Food and Drug Safety, supporting its ability to supply regulated global markets.

CFO: IPO to strengthen the balance sheet

The IPO comes at a time when Symbiotec is looking to strengthen its financial position while continuing to build its manufacturing and product capabilities.

Of the ₹1,757-crore issue, ₹150 crore represents fresh capital, while the remaining ₹1,607 crore is an offer for sale by existing shareholders. The company has stated that the fresh-issue proceeds will be used towards repayment or prepayment of certain outstanding borrowings and general corporate purposes.

Raghavender Ramachandran, CFO reiterated that,“The IPO is an important step in strengthening our balance sheet and creating a stronger financial platform for the next phase of Symbiotec’s growth. As we expand our product portfolio and deepen our global customer relationships, financial flexibility will remain an important part of our strategy.”

The company has reported a 10.16% CAGR in revenue, with institutional investors including Actis and Franklin Templeton among its investors”.

Global opportunity, but risks remain

While Symbiotec’s specialised portfolio and global regulatory footprint provide important competitive advantages, investors will also need to evaluate the risks associated with the business.

Key areas include customer and revenue concentration, regulatory and compliance requirements, geopolitical and supply-chain vulnerabilities, operational and structural risks, and valuation considerations.

For a company operating across highly regulated pharmaceutical markets, maintaining regulatory compliance across multiple jurisdictions remains critical. Similarly, dependence on specialised raw materials, global supply chains and international customers can expose the business to external disruptions.

The large offer-for-sale component of the IPO also means that a significant portion of the issue proceeds will accrue to selling shareholders rather than directly to the company, while the fresh issue is primarily intended for debt reduction and corporate purposes.

Symbiotec Pharmalab Limited IPO details at a glance

The Anchor Investor bidding period is scheduled for August 21, while the public issue opens on August 24 and closes on August 27. The price band is ₹938-₹988 per share and the minimum bid lot is 15 shares. Eligible employees will receive a ₹90-per-share discount on their bids under the employee reservation portion.

The issue is being managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India) as the book-running lead managers.

For Symbiotec, however, the IPO represents more than a capital-market event. It marks the next stage in a journey that began with a scientist’s fascination for molecules and has evolved into a specialised pharmaceutical business with global ambitions.

The company’s stated objective now is clear: to move from being a strong global steroid-API player to becoming a broader, globally recognised platform across steroidal hormones, APIs and complex pharmaceutical technologies.

Symbiotec Pharmalab IPO — Short Snapshot

IPO Size: ₹1,757 crore
Fresh Issue: ₹150 crore
Offer for Sale: ₹1,607 crore
Price Band: ₹938–₹988 per share
IPO Opens: August 24, 2026
IPO Closes: August 27, 2026
Anchor Bidding: August 21, 2026
Minimum Lot: 15 shares
Listing: BSE & NSE
Fresh Issue Proceeds: Repayment/prepayment of borrowings and general corporate purposes
Business: Biopharmaceutical CDMO specialising in corticosteroid and steroid-hormone APIs
Global Presence: 200+ customers across 40+ countries
Key Strength: 38.20% global market share in corticosteroid APIs

The IPO is largely an Offer for Sale, with only ₹150 crore flowing into the company through the fresh issue.

Disclaimer: This article is for information purpose only and is not investment advice. Please read the IPO documents carefully before investing.

Kindly Like the shared link and Subscribe our channel. https://youtu.be/pwpH-IXaba4 https://youtube.com/shorts/NOqhSoAa834?feature=share